Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Reexamination Certificate
2007-02-27
2007-02-27
Rawlings, Stephen L. (Department: 1643)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
C435S328000, C530S387300
Reexamination Certificate
active
10143437
ABSTRACT:
The invention relates to a method of preparing heteromultimeric polypeptides such as bispecific antibodies, bispecific immunoadhesins and antibody-immunoadhesin chimeras. The invention also relates to the heteromultimers prepared using the method. Generally, the method provides a multispecific antibody having a common light chain associated with each heteromeric polypeptide having an antibody binding domain. Additionally the method futher involves introducing into the multispecific antibody a specific and complementary interaction at the interface of a first polypeptide and the interface of a second polypeptide, so as to promote heteromultimer formation and hinder homomultimer formation; and/or a free thiol-containing residue at the interface of a first polypeptide and a corresponding free thiol-containing residue in the interface of a second polypeptide, such that a non-naturally occurring disulfide bond is formed between the first and second polypeptide. The method allows for the enhanced formation of the desired heteromultimer relative to undesired heteromultimers and homomultimers.
REFERENCES:
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 5116964 (1992-05-01), Capon et al.
patent: 5591828 (1997-01-01), Bosslet et al.
patent: 5731168 (1998-03-01), Carter et al.
patent: 5807706 (1998-09-01), Carter et al.
patent: 5821333 (1998-10-01), Carter et al.
patent: 314317 (1989-05-01), None
patent: WO 89/02922 (1989-04-01), None
patent: WO 91/08298 (1991-06-01), None
patent: WO 92/10209 (1992-06-01), None
patent: WO 92/22653 (1992-12-01), None
patent: WO 93/06217 (1993-04-01), None
patent: WO 93/11162 (1993-06-01), None
patent: WO 96/27011 (1996-09-01), None
patent: WO 96/37621 (1996-11-01), None
Reiter Y, et al. Protein Eng. May 1994; 7 (5): 697-704.
Luo D, et al. J Biochem (Tokyo). Oct. 1995; 118 (4): 825-31.
Nieba L, et al. Protein Eng. Apr. 1997; 10 (4): 435-4.
Barton, “Protein sequence alignment and database scanning”Protein Structure Predictionpp. 31-63 (1996).
Berg et al., “Bispecific Antibodies that Mediate Killing of Cells Infected with Human Immunodeficiency Virus of Any Strain”Proc. Natl. Acad. Sci. USA88:4723-4727 (Jun. 1991).
Berman et al., “Protection from Genital Herpes Simplex Virus Type 2 Infection by Vaccination with Cloned Type 1 Glycoprotein D”Science227 (4693) :1490-1492 (Mar. 22, 1985).
Byrn et al., “Biological Properties of a CD4 Immunoadhesin”Nature344 :667-670 (Apr. 12, 1990).
Carter et al., “Engineering Subtilisin BPN' for Site-Specific Proteolysis”Proteins: Struct. Funct., Genet., 6:240-248 (1989).
Carter et al., “High LevelEscherichia coliExpression and Production of a Bivalent Humanized Antibody Fragment.”Bio/Technology. 10:163-167 (1992).
Carter et al., “Humanization of an Anti-p185HER2Antibody for Human Cancer Therapy”Proc. Natl. Acad. Sci. USA89:4285-4289 (May 1992).
Chamow et al., “A Humanized, Bispecific Immunoadhesin-Antibody That Retargets CD3+ Effectors to Kill HIV-1-Infected Cells”Journal of Immunology153:4268-4280 (1994).
Chothia and Leak, “Canonical Structures for the Hypervariable Regions of Immunoglobulins”J. Mol. Biol196:901-917 (1987).
Clackson et al., “Making Antibody Fragments Using Phage Display Libraries.”Nature. 352:624-628 (1991).
de Kruif et al., “Leucine Zipper Dimerized Bivalent and Bispecific scFv Antibodies from a Semi-synthetic Antibody Phage Display Library”Journal of Biological Chemistry271(13):7630-7634 (Mar. 29, 1996).
Dietsch et al., “Bispecific Receptor Globulins, Novel Tools for the Study of Cellular Interactions”Journal of Immunological Methods162:123-132 (1993).
Ellison et al., “The nucleotide sequence of a human immunoglobulin Cy1gene”Nucleic Acids Research10(13):4071-4079 (1982).
Ellman et al., “Biosynthetic Method for Introducing Unnatural Amino Acids Site-Specifically into Proteins”Meth. Enzym. 202:301-336 (1991).
Fanger et al., “Bispecific Antibodies”Critical Reviews in Immunology12(3,4):101-124 (1992).
Feng et al., “Aligning Amino Acid Sequences: Comparison of Commonly Used Methods”J. Mol. Evol. 21:112-125 (1985).
Feng et al., “Progressive Alignment and Phylogenetic Tree Construction of Protein Sequences”Methods in Enzymology183:375-387 (1990).
Feng et al., “Progressive Sequence Alignment as a Prerequisite to Correct Phylogenetic Trees”J. Mol. Evol. 25:351-360 (1987).
Figini et al., “In Vitro Assembly of Repertoires of Antibody Chains on the Surface of Phage by Renaturation”J. Mol. Biol. 239:68-78 (1994).
George et al., “Current Methods in Sequence Comparison and Analysis”Macromolecular Sequencing and Synthesispp. 127-149 (1988).
Griffiths et al., “Isolation of High Affinity Human Antibodies Directly From Large Synthetic Repertoires”EMBO Journal13:3245-3260 (1994).
Gruber et al., “Efficient Tumor Cell Lysis Mediated by a Bispecific Single Chain Antibody Expressed inEscherichia coli” Journal of Immunology152:5368-5374 (1994).
Hammerling et al., “Use of hybrid antibody with anti-γG and anti-ferritin specificities in locating cell surface antigens by electron microscopy”Journal of Experimental Medicine128:1461-1469 (1968).
Hawkins et al., “Selection of Phage Antibodies by Binding Affinity Mimicking Affinity Maturation”J. Mol. Biol. 226:889-896 (1992).
Holliger et al., “Diabodies: Small Bivalent and Bispecific Antibody Fragments.”Proc. Natl. Acad. Sci. USA90:6444-48 (Jul. 1993).
Kabat et al.Sequences of Proteins of Immunological Interest, 5th edition, Bethesda, MD:NIH vol. 1:688-696 (1991).
Kostelny et al., “Formation of a Bispecific Antibody by the Use of Leucine Zippers”Journal of Immunology148(5):1547-1553 (1992).
Lasky et al., “DNA sequence analysis of the type-common glycoprotein-D genes of herpes simplex virus types 1 and 2”DNA3(1):23-29 (1984).
Le Doussal et al., “Bispecific Monoclonal Antibody-Mediated Targeting of an Indium-111-Labeled DTPA Dimer to Primary Colorectal Tumors: Pharmacokinetics, Biodistribution, Scintigraphy and Immune Response”J. Nucl. Med. 34:1662-1671 (1993).
Le Doussal et al., “Bispecific-Antibody-Mediated Targeting of Radiolabeled Bivalent Haptens:Theoretical, Experimental and Clinical Results”Int. J. Cancer Suppl. 7:58-62 (1992).
Marks et al., “By-Passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling”Bio/Technology10:779-783 (1992).
Marks et al., “By-Passing Immunization: Human Antibodies From V-gene Libraries Displayed On Phage.”J. Mol. Biol. 222:581-597 (1991).
McCafferty et al., “Phage antibodies: filamentous phage displaying antibody variable domains”Nature348:552-554 (1990).
Nissim et al., “Antibody fragments for a ‘single pot’ phage display library as immunochemical reagnets”EMBO Journal13(3):692-698 (1994).
Nolan et al., “Bifunctional antibodies: concept, production and applications”Biochimica et Biophysica Acta1040:1-11 (1990).
Presta et al., “Humanization of an Antibody Directed Against IgE”J. Immunol. 151(5):2623-2632 (Sep. 1, 1993).
Ridgway et al., “‘Knobs-into-holes’ Engineering of Antibody CH3 Domains for Heavy Chain Heterodimerization”Protein Engineering9(7):617-621 (1996).
Rodrigues et al., “Engineering a humanized bispecific F(ab')2fragment for improved binding to T cells”Int. J. Cancer(Suppl.) 7:45-50 (1992).
Segal et al., “Targeting and Activation of Cytotoxic Lymphocytes”Chem. Immunol. 47:179-213 (1989).
Shalaby et al., “Development of Humanized Bispecific Antibodies Reactive with Cytotoxic Lymphocytes and Tumor Cells Overexpressing the HER2 Protooncogene”Journal of Experimental Medicine175:217-225 (Jan. 1, 1992).
Songsivilai et al., “Bispecifici antibody: a
Arathoon W. Robert
Carter Paul J.
Merchant Anne M.
Presta Leonard G.
Genentech Inc.
Merchant & Gould P.C.
Rawlings Stephen L.
LandOfFree
Method for making multispecific antibodies having... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for making multispecific antibodies having..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for making multispecific antibodies having... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3826250